Europe:+32-2-535-7543
Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
  • Japanese
  • Korean
  • Chinese
Cover Image

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Non-Alcoholic Steatohepatitis 7
  • Report Guidance 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Unaccomplished Trials of Non-Alcoholic Steatohepatitis 26
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 31
  • Prominent Drugs 32
  • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 33
  • May 04, 2015: Islet Sciences Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH 33
  • Apr 23, 2015: Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis 33
  • Apr 23, 2015: Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients 34
  • Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 35
  • Apr 21, 2015: Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor 36
  • Apr 21, 2015: Upcoming AACR and EASL poster presentations support Nimbus' novel, liver-directed approach to allosteric ACC inhibition across liver disease spectrum, including NASH and HCC 36
  • Apr 20, 2015: NGM Biopharmaceuticals to Present New Data on NGM282 at the European Association for the Study of the Liver International Liver Congress 2015 37
  • Apr 08, 2015: Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015 37
  • Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 38
  • Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 38
  • Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 39
  • Mar 20, 2015: Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH 40
  • Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 41
  • Mar 12, 2015: Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA 41
  • Mar 09, 2015: Islet Sciences COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH) 42
  • Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 42
  • Feb 25, 2015: MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina 43
  • Feb 24, 2015: Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 43
  • Clinical Trial Profiles 45
  • Clinical Trial Overview of Top Companies 45
  • Genextra S.p.a. 45
  • Clinical Trial Overview of Genextra S.p.a. 45
  • Genfit SA 46
  • Clinical Trial Overview of Genfit SA 46
  • Cempra, Inc. 47
  • Clinical Trial Overview of Cempra, Inc. 47
  • Raptor Pharmaceuticals Corp. 48
  • Clinical Trial Overview of Raptor Pharmaceuticals Corp. 48
  • Nimbus Therapeutics, LLC 49
  • Clinical Trial Overview of Nimbus Therapeutics, LLC 49
  • Immuron Limited 50
  • Clinical Trial Overview of Immuron Limited 50
  • Gilead Sciences, Inc. 51
  • Clinical Trial Overview of Gilead Sciences, Inc. 51
  • Galmed International Ltd. 52
  • Clinical Trial Overview of Galmed International Ltd. 52
  • Galectin Therapeutics, Inc. 53
  • Clinical Trial Overview of Galectin Therapeutics, Inc. 53
  • DURECT Corporation 54
  • Clinical Trial Overview of DURECT Corporation 54
  • Clinical Trial Overview of Top Institutes / Government 55
  • The National Institute of Diabetes and Digestive and Kidney Diseases 55
  • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 55
  • Tehran University of Medical Sciences 56
  • Clinical Trial Overview of Tehran University of Medical Sciences 56
  • University of California, San Diego 57
  • Clinical Trial Overview of University of California, San Diego 57
  • National Nutrition and Food Technology Research Institute 58
  • Clinical Trial Overview of National Nutrition and Food Technology Research Institute 58
  • Yokohama City University 59
  • Clinical Trial Overview of Yokohama City University 59
  • Bambino Gesu Hospital and Research Institute 60
  • Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 60
  • Ghent University Hospital 61
  • Clinical Trial Overview of Ghent University Hospital 61
  • Gunma Liver Study Group 62
  • Clinical Trial Overview of Gunma Liver Study Group 62
  • Hadassah Medical Organization 63
  • Clinical Trial Overview of Hadassah Medical Organization 63
  • Hiroshima University Hospital 64
  • Clinical Trial Overview of Hiroshima University Hospital 64
  • Five Key Clinical Profiles 65

Appendix 91

  • Abbreviations 91
  • Definitions 91
  • Research Methodology 92
  • Secondary Research 92
  • About GlobalData 93
  • Contact Us 93
  • Disclaimer 93
  • Source 93

List of Tables

List of Tables

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2015* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 14
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2015* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Terminated Clinical Trials, 2015* 27
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2015* 45
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Genfit SA, 2015* 46
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cempra, Inc., 2015* 47
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Raptor Pharmaceuticals Corp., 2015* 48
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nimbus Therapeutics, LLC, 2015* 49
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Immuron Limited, 2015* 50
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2015* 51
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2015* 52
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Galectin Therapeutics, Inc., 2015* 53
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by DURECT Corporation, 2015* 54
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2015* 55
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2015* 56
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2015* 57
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Nutrition and Food Technology Research Institute, 2015* 58
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yokohama City University, 2015* 59
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2015* 60
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Ghent University Hospital, 2015* 61
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Gunma Liver Study Group, 2015* 62
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2015* 63
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hiroshima University Hospital, 2015* 64

List of Figures

List of Figures

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 14
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
  • GlobalData Methodology 92
Show More
Pricing
Back to Top